Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingtongping is a Traditional Chinese Medicine (TCM) granule formulation developed by Beijing Rongzhiyuan Pharmaceutical Technology for the treatment of primary dysmenorrhea. The drug is composed of multiple herbal ingredients intended to promote blood circulation, resolve blood stasis, and regulate Qi to alleviate menstrual pain. It has undergone Phase II and Phase III clinical trials in China, demonstrating efficacy in reducing the severity and duration of symptoms associated with primary dysmenorrhea. The formulation specifically targets the underlying TCM patterns of cold-dampness stagnation and blood stasis, which are common clinical presentations of menstrual cramps. As a TCM product, it aims to address the root cause of pain by restoring physiological balance and improving microcirculation in the uterine environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jingtongping.